Recombinant Krs-2 Monoclonal Antibody (AN301176L)
For research use only.
| Verified Samples | Verified Samples in WB: 3T3-L1 |
| Dilution | WB 1:2000-1:10000 |
| Isotype | IgG,κ |
| Host | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Recombinant Human Krs-2 protein |
| Abbre | Krs-2 |
| Synonyms | STK, MST, YSK, KRS, BCC, LFS, TRP, Antigen NY-CO, Tumor protein, Tumor protein p, Phosphoprotein p, Tumor suppressor p, Mutant tumor protein, serine/threonine kinase, Cellular tumor antigen p, Transformation related protein, STK4, KRS2, MST1, YSK3, serine/threonine kinase 4, Antigen NY-CO-13, BCC7, Cellular tumor antigen p53, FLJ92943, LFS1, Mutant tumor protein 53, p53, p53 tumor suppressor, Phosphoprotein p53, TIIAC, Tp53, Transformation related protein 53, TRP53, Tumor protein 53, Tumor protein p53, Tumor suppressor p53, KRS2, MST1, serine/threonine kinase 4, YSK3, Kinase responsive to stress, Mammalian STE20 like protein kinase 1, Mammalian STE20-like protein kinase 1, Mammalian sterile 20 like 1, MST-1, Serine/threonine protein kinase Krs 2, Serine/threonine-protein kinase 4, Serine/threonine-protein kinase Krs-2, STE20 like kinase MST1, STE20-like kinase MST1, Krs 2 |
| Swissprot | |
| Calculated MW | 56 kDa |
| Observed MW |
56 kDa
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Cytoplasm, Nucleus, The caspase-cleaved form cycles between nucleus and cytoplasm (PubMed:19525978, PubMed:11278283). Phosphorylation at Thr-117 leads to inhibition of nuclear translocation (PubMed:19525978). |
| Concentration | 0.2 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A |
| Research Areas | Signal Transduction, Cardiovascular |
| Clone No. | 9D2 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | STK3(serine/threonine kinase 3) Homo sapiens This gene encodes a serine/threonine protein kinase activated by proapoptotic molecules indicating the encoded protein functions as a growth suppressor. Cleavage of the protein product by caspase removes the inhibitory C-terminal portion. The N-terminal portion is transported to the nucleus where it homodimerizes to form the active kinase which promotes the condensation of chromatin during apoptosis. Multiple transcript variants encoding different isoforms have been found for this gene. |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
